Biotech earnings arrive after dreadful 6 months, but upcoming readouts offer hope to analysts SCOOP: Eisai closing oncology R&D wing H3 Biomedicine for good Editas fills empty CMO role with Sanofi's rare disease, blood disorder chief Sesen slams brakes on phase 3 bladder cancer program to save cash as it looks for off-ramp Nestlé wagers $41M on Enterome's preclinical food allergy and IBD prospect Kyowa Kirin axes Parkinson's med, saying development and regulatory hurdles are too daunting Validated by early COVID shot investment, Oxford Science Enterprises clinches £250M for emerging science and spinouts Straight from science fiction, bacteria-based 'microrobots' could become a future cancer treatment The top 10 generic drug makers by 2021 revenue Medtronic issues EU recall for implantable defibrillators that may not emit strong enough shocks CMS to raise hospital payments to buy N95 masks, proposes 2.7% pay hike for facilities From joint manufacturing to 'hub-and-spoke' localization, pharma's supply chain future will be a team effort: report HHS renews COVID-19 public health emergency another 3 months Featured Story | By James Waldron With signs that biotech’s nosedive may be starting to level off, will the sector’s big players use their second-quarter earnings results to point to green shoots? read more |
| |
|---|
|
Top Stories By Max Bayer Japanese Big Pharma Eisai is shutting down its U.S.-based oncology R&D wing, H3 Biomedicine, saying the operation was "complete." As a result, the company is laying off 88 staffers. read more By Annalee Armstrong Editas has finally filled a vacant chief medical officer role, five months after Lisa Michaels left without explanation. Baisong Mei, M.D., Ph.D., will take over the chief drug development role at the gene editing biotech. read more By Nick Paul Taylor Sesen Bio is pumping the brakes on its phase 3 bladder cancer program. After weighing up what it will take to get Vicineum to market, the biotech has paused clinical development in the U.S. to preserve the cash that could be key to its exit. read more By Nick Paul Taylor Nestlé Health Science has returned to the deal table once again, putting down 40 million euros ($41 million) to co-develop Enterome’s preclinical IL-10 inducer and collaborate on the discovery of other food allergy candidates. read more By Max Bayer Kyowa Kirin is axing a phase 2 Parkinson's disease treatment, saying the future development and regulatory hurdles facing the med are too daunting. The drug was set to be a successor to FDA-approved Nourianz. read more By Gabrielle Masson Oxford Science Enterprises—a founding investor in Vaccitech, the biotech that helped develop the Oxford/AstraZeneca COVID-19 vaccine—has raised £250 million ($300 million), bringing the venture capital firm’s total raised to more than £850 million ($1 billion). read more By Max Bayer New research from Germany hints at the promise of treating cancer with bacteria-based 'microrobots' armed with nanoliposomes containing immune system-triggering drugs. The scientists found that the bacteria, guided by magnets, was more effective at killing cancer cells than a control group. read more By Kevin Dunleavy,Zoey Becker,Fraiser Kansteiner,Angus Liu,Eric Sagonowsky Many producers of generic drugs have struggled to achieve growth in recent years due to pricing pressures. But there are promising signs that the industry is ready for an uptick, and they were evident in 2021 as eight of the top 10 companies by generics sales realized growth. read more By Andrea Park Medtronic is warning European healthcare providers of a potential safety issue found within many of its implanted heart devices that may make them less effective. read more By Robert King CMS is proposing to offer enhanced Medicare payments to hospitals for buying domestically manufactured N95 masks in an attempt to avert supply chain shortages previously felt during the pandemic. read more By Fraiser Kansteiner Pharmaceutical supply chains have proven remarkably resilient during the COVID-19 pandemic. Still, that’s not to say drugmakers’ supply chains have made it through the past two-and-a-half years unscathed. Companies have reported difficulties getting their hands on raw materials and consumables, and at times they've had to compete with COVID-19 vaccine manufacturers for those same resources. read more By Robert King HHS Secretary Xavier Becerra has extended the COVID-19 public health emergency for another 90 days and with it key regulatory flexibilities. read more | | YOU vs. “UNSOLVABLE” PROBLEMS Let’s solve patient needs together. Turn promise into reality and become part of something bigger, today. Explore meaningful careers here. |
|---|
Resources Sponsored by: NetApp Could cloud be the cure for your EHR headaches? See our infographic on how moving to the cloud can slash financial and administrative burdens. Sponsored by: Lumanity Join us, as we explore the commercial readiness challenges and practical realities of driving a successful launch in the cell and gene therapy space. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Decentralized Clinical Trials Forum July 26, 2022 | Free Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Health Payer Forum October 12, 2022 | Free Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Clinical Quality Oversight Forum: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia PA | Presented by: Fierce Pharma Decentralized Clinical Trials Summit: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia, PA | Presented by: Fierce Pharma Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Free Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual Fierce Clinical Trial Billing & Research Compliance Summit February 2023 | Location TBD Fierce BD&L Summit for Life Sciences March 14-15, 2023 | San Francisco, CA | 